Lido Advisors
BIO icon

Lido Advisors’s Bio-Rad Laboratories Class A BIO Stock Holding History

Lido Advisors’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-808
Closed -$225K – 2142
2026
Q1 		$225K Buy
+808
New +$233K ﹤0.01% 1721
2025
Q1 		– Sell
-757
Closed -$249K – 1528
2024
Q4 		$249K Sell
757
-15
-2% -$5.09K ﹤0.01% 1299
2024
Q3 		$258K Buy
772
+24
+3% +$7.62K ﹤0.01% 1220
2024
Q2 		$204K Sell
748
-721
-49% -$210K ﹤0.01% 1281
2024
Q1 		$508K Sell
1,469
-603
-29% -$198K ﹤0.01% 898
2023
Q4 		$669K Buy
2,072
+842
+68% +$264K ﹤0.01% 752
2023
Q3 		$441K Buy
1,230
+411
+50% +$159K ﹤0.01% 783
2023
Q2 		$310K Buy
+819
New +$333K ﹤0.01% 916

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Lido Advisors's BIO Position: Q2 2026 in Review

Lido Advisors sold out of Bio-Rad Laboratories Class A (BIO) in Q2 2026, closing a stake of 808 shares — an estimated $225K sold.

Lido Advisors first reported a position in BIO in Q2 2023 and held it in 8 quarters. The position peaked at $669K in Q4 2023. 399 funds tracked by Wall St. Rank hold BIO as of Q2 2026.

  • Lido Advisors reported no remaining Bio-Rad Laboratories Class A position as of Q2 2026 after selling out during the quarter.
  • Lido Advisors sold 808 Bio-Rad Laboratories Class A shares in Q2 2026, an estimated $225K.
  • Lido Advisors first reported a position in Bio-Rad Laboratories Class A in Q2 2023 and held it in 8 quarters.
  • Lido Advisors's Bio-Rad Laboratories Class A position peaked at $669K in Q4 2023.
  • 399 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.

Based on Lido Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.